pancreatic cancer
Conditions
Interventions
Drug-resistant group and non-drug-resistant group:None
Cancer and paracancerous group:None
Sponsors
Huzhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Collect tumor tissue samples from 3 clinical gemcitabine-sensitive (SENS) and 3 gemcitabine-resistant (RESIS) pancreatic cancer patients: 1. Pancreatic cancer surgery patients at our center, aged >=18 years; 2. Patients who received neoadjuvant chemotherapy before surgery; 3. Patients who received a gemcitabine regimen for neoadjuvant chemotherapy; 4. Signed informed consent. Collect 16 tumor and adjacent tissue samples from pancreatic cancer patients: 1. Pathologically diagnosed with pancreatic cancer; 2. Aged >=18 years; 3. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Unable to obtain the patient's imaging and oncological indicator test reports before and after neoadjuvant therapy; 2. Unable to obtain specific data on the patient's chemotherapy cycles and surgical treatment; 3. The interval between the end of the patient's neoadjuvant therapy and surgery is greater than 8 weeks; 4. Unable to obtain the patient's resected pancreatic cancer tissue specimen; 5. The patient's specimen cannot undergo transcriptome sequencing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Suppressor of Zeste 12 protein homolog; | — |
Countries
China
Contacts
Public ContactYin Lei
Huzhou Central Hospital
Outcome results
None listed